hPYY(3-36) injections have shown positive effects on appetite regulations, sparking increased interest in hPYY(3-36) research. Of great interest is oral delivery of hPYY(3-36) that can achieve clinically relevant weight-loss outcomes in what would be a highly patient compliant route. Successful oral delivery of other peptides utilizing the vitamin B 12 pathway has been shown but below clinically relevant levels. Herein, we present clinically relevant in vivo oral delivery of B 12-hPYY(3-36) conjugates.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journal of Medicinal Chemistry|
|State||Published - Dec 22 2011|
ASJC Scopus subject areas
- Molecular Medicine
- Drug Discovery